$ISRG

Intuitive Surgical (ISRG) and Stryker (SYK) both reported strong Q2 2026 earnings, with ISRG highlighting 85% recurring revenue and SYK showing 9.4% revenue growth. ISRG's da Vinci systems and SYK's MedSurg and Neurotechnology segments drove performance. ISRG's CEO noted portfolio strength, while SYK's CEO cited regained momentum. Analysts favor ISRG for its compounding moat and recurring revenue model, with 25 EPS revisions in 30 days.

Intuitive Surgical (ISRG) and Novo Nordisk (NVO) are highlighted as potential investment opportunities despite recent stock declines. ISRG is down 34% YTD due to lower margins on its da Vinci 5 system, but its features may expand market share. NVO has lost 8% YTD amid competition in the GLP-1 weight loss market, but its pipeline, including amycretin and UBT251, shows promise.

Intuitive Surgical received FDA approval for its flexible gastrointestinal robot, IG1000, marking its entry into a market dominated by Olympus. The company plans to refine the product before commercial launch, focusing on clinical benefits and user experience. Analysts note the product's force feedback and suturing capabilities, highlighting Intuitive's strategic expansion beyond its da Vinci surgical robots.

NIKE (NKE) and Intuitive Surgical (ISRG) shares have underperformed in 2026. NIKE reported Q4 adjusted EPS of $0.20, beating estimates, but revenue declined 1%. ISRG's Q2 adjusted EPS rose 27.9%, topping estimates, with revenue up 18.5%. Both face challenges, with NIKE struggling with sales declines and ISRG dealing with valuation concerns and slower procedure growth.

Intuitive Surgical (ISRG) stock is down 21% over the past year due to concerns about U.S. procedure growth slowdown. However, the company placed 468 da Vinci systems in the latest quarter, an 18% increase year-over-year, with U.S. placements up 24%. Hospitals are investing in the da Vinci platform, suggesting confidence in future demand. System placements drive recurring revenue, which accounts for 85% of ISRG's total revenue.

Abbott Laboratories (NYSE:ABT) and Intuitive Surgical (NASDAQ:ISRG) reported strong quarterly results, with Abbott raising its annual profit outlook and Intuitive beating revenue and earnings expectations. Abbott's diversification across diagnostics, medical devices, and nutrition drove growth, while Intuitive's robotic surgery ecosystem and recurring revenue model supported its performance. Despite the positive results, Intuitive's shares declined due to slowing domestic procedure growth. Abbot

Danaher (DHR) and Intuitive Surgical (ISRG) present contrasting growth paths. Danaher benefits from improving life sciences spending, with strong bioprocessing orders and $100M revenue shifted to next year. Intuitive Surgical reports 18% YoY growth in da Vinci system placements, 70% non-GAAP gross margin, and 85% recurring revenue. Investors must decide between cyclical recovery and structural growth.

Analysts maintain positive outlook on Intuitive Surgical (ISRG), with Citigroup's Joanne Wuensch setting a $500 price target, implying 33.5% upside. The mean target is $483.34, with a high of $685, suggesting 82.9% potential gain.

Intuitive Surgical (ISRG) EVP Mark Brosius sold 154 shares of common stock in two transactions on August 20 and 21, 2026, at $396.37 and $375.57 per share. The sales were made under a pre-arranged 10b5-1 trading plan, which expires on February 14, 2027. Brosius now holds 881 shares directly.

Intuitive Surgical (ISRG) plans to open a new manufacturing facility in Penang, Malaysia, by 2028 to produce components for its da Vinci surgical system. The move aims to enhance supply resilience and regional access in Asia Pacific. The company reported Q2 2026 revenue of $2.89 billion and net income of $818.1 million, with projections of $15.6 billion revenue and $4.7 billion earnings by 2029.